;PMID: 6587382
;source_file_1236.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..48] = [t:0..48]
;1)sentence:[e:53..137] = [t:53..137]
;2)section:[e:141..210] = [t:141..210]
;3)sentence:[e:214..332] = [t:214..332]
;4)sentence:[e:333..500] = [t:333..500]
;5)sentence:[e:501..604] = [t:501..604]
;6)sentence:[e:605..817] = [t:605..817]
;7)section:[e:821..865] = [t:821..865]

;section 0 Span:0..48
;Proc Natl Acad Sci U S A  1984 Jun;81(12):3670-4
(SEC
  (FRAG (NNP:[0..4] Proc) (NNP:[5..9] Natl) (NNP:[10..14] Acad)
        (NNP:[15..18] Sci) (NNP:[19..20] U) (NNP:[21..22] S) (NNP:[23..24] A)
        (CD:[26..30] 1984) (::[31..38] Jun;81-LRB-) (CD:[38..40] 12)
        (-RRB-:[40..41] -RRB-) (CD:[41..46] :3670) (::[46..47] -)
        (CD:[47..48] 4)))

;sentence 1 Span:53..137
;Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma 
;cells.
;[83..88]:gene-rna:"N-ras"
;[101..136]:malignancy:"SW-1271 human lung carcinoma  cells"
(SENT
  (NP-HLN
    (NP (NN:[53..62] Mechanism))
    (PP (IN:[63..65] of)
      (NP
        (NP (NN:[66..76] activation))
        (PP (IN:[77..79] of)
          (NP
            (NP (DT:[80..82] an) (NN:[83..88] N-ras) (NN:[89..97] oncogene))
            (PP (IN:[98..100] of)
              (NP (NN:[101..108] SW-1271) (JJ:[109..114] human)
                  (NN:[115..119] lung) (NN:[120..129] carcinoma)
                  (NNS:[131..136] cells)))))))
    (.:[136..137] .)))

;section 2 Span:141..210
;Yuasa Y, Gol RA, Chang A, Chiu IM, Reddy EP, Tronick SR, Aaronson SA.
(SEC
  (FRAG (NNP:[141..146] Yuasa) (NNP:[147..148] Y) (,:[148..149] ,)
        (NNP:[150..153] Gol) (NNP:[154..156] RA) (,:[156..157] ,)
        (NNP:[158..163] Chang) (NNP:[164..165] A) (,:[165..166] ,)
        (NNP:[167..171] Chiu) (NNP:[172..174] IM) (,:[174..175] ,)
        (NNP:[176..181] Reddy) (NNP:[182..184] EP) (,:[184..185] ,)
        (NNP:[186..193] Tronick) (NNP:[194..196] SR) (,:[196..197] ,)
        (NNP:[198..206] Aaronson) (NNP:[207..209] SA) (.:[209..210] .)))

;sentence 3 Span:214..332
;An N-ras-related transforming gene was detected in the human lung carcinoma
;cell  line SW-1271 and molecularly cloned.
;[217..222]:gene-rna:"N-ras"
;[275..308]:malignancy:"lung carcinoma cell  line SW-1271"
(SENT
  (S
    (NP-SBJ-1 (DT:[214..216] An)
      (ADJP (NN:[217..222] N-ras) (HYPH:[222..223] -) (VBN:[223..230] related))
      (VBG:[231..243] transforming) (NN:[244..248] gene))
    (VP (VBD:[249..252] was)
      (VP
        (VP (VBN:[253..261] detected)
          (NP-1 (-NONE-:[261..261] *))
          (PP (IN:[262..264] in)
            (NP
              (NP (DT:[265..268] the) (JJ:[269..274] human) (NN:[275..279] lung)
                  (NN:[280..289] carcinoma) (NN:[290..294] cell)
                  (NN:[296..300] line))
              (NP (NN:[301..308] SW-1271)))))
        (CC:[309..312] and)
        (VP
          (ADVP (RB:[313..324] molecularly))
          (VBN:[325..331] cloned)
          (NP-1 (-NONE-:[331..331] *)))))
    (.:[331..332] .)))

;sentence 4 Span:333..500
;The lesion responsible for its acquisition  of transforming activity was
;localized to a single nucleotide transition from A  to G in codon 61 of the
;predicted protein.
;[439..449]:variation-type:"transition"
;[455..456]:variation-state-original:"A"
;[461..462]:variation-state-altered:"G"
;[466..474]:variation-location:"codon 61"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[333..336] The) (NN:[337..343] lesion))
      (ADJP (JJ:[344..355] responsible)
        (PP (IN:[356..359] for)
          (NP
            (NP (PRP$:[360..363] its) (NN:[364..375] acquisition))
            (PP (IN:[377..379] of)
              (NP (VBG:[380..392] transforming) (NN:[393..401] activity)))))))
    (VP (VBD:[402..405] was)
      (VP (VBN:[406..415] localized)
        (NP-1 (-NONE-:[415..415] *))
        (PP (TO:[416..418] to)
          (NP
            (NP (DT:[419..420] a) (JJ:[421..427] single)
                (NN:[428..438] nucleotide) (NN:[439..449] transition))
            (PP (IN:[450..454] from)
              (NP (NN:[455..456] A)))
            (PP (TO:[458..460] to)
              (NP (NN:[461..462] G)))))
        (PP-LOC (IN:[463..465] in)
          (NP
            (NP (NN:[466..471] codon) (CD:[472..474] 61))
            (PP (IN:[475..477] of)
              (NP (DT:[478..481] the) (VBN:[482..491] predicted)
                  (NN:[492..499] protein)))))))
    (.:[499..500] .)))

;sentence 5 Span:501..604
;This lesion in the second exon  results in the substitution of arginine for
;glutamine at this position.
;[520..531]:variation-location:"second exon"
;[548..560]:variation-type:"substitution"
;[564..572]:variation-state-altered:"arginine"
;[577..586]:variation-state-original:"glutamine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[501..505] This) (NN:[506..512] lesion))
      (PP (IN:[513..515] in)
        (NP (DT:[516..519] the)
           (JJ:[520..526] second) (NN:[527..531] exon))))
    (VP (VBZ:[533..540] results)
      (PP (IN:[541..543] in)
        (NP
          (NP (DT:[544..547] the) (NN:[548..560] substitution))
          (PP (IN:[561..563] of)
            (NP (NN:[564..572] arginine)))
          (PP (IN:[573..576] for)
            (NP (NN:[577..586] glutamine)))))
      (PP-LOC (IN:[587..589] at)
        (NP (DT:[590..594] this) (NN:[595..603] position))))
    (.:[603..604] .)))

;sentence 6 Span:605..817
;These  findings, together with previous studies, indicate that the activation
;of ras  oncogenes in human tumors is most commonly due to point mutations at
;one of two  major "hot spots" in the ras coding sequence.
;[686..689]:gene-rna:"ras"
;[741..756]:variation-type:"point mutations"
;[797..800]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ (DT:[605..610] These) (NNS:[612..620] findings))
    (,:[620..621] ,)
    (ADVP (RB:[622..630] together)
      (PP (IN:[631..635] with)
        (NP (JJ:[636..644] previous) (NNS:[645..652] studies))))
    (,:[652..653] ,)
    (VP (VBP:[654..662] indicate)
      (SBAR (IN:[663..667] that)
        (S
          (NP-SBJ
            (NP (DT:[668..671] the) (NN:[672..682] activation))
            (PP (IN:[683..685] of)
              (NP (NN:[686..689] ras) (NNS:[691..700] oncogenes)))
            (PP-LOC (IN:[701..703] in)
              (NP (JJ:[704..709] human) (NNS:[710..716] tumors))))
          (VP (VBZ:[717..719] is)
            (ADVP (RBS:[720..724] most) (RB:[725..733] commonly))
            (PP-PRD (JJ:[734..737] due)
              (PP (TO:[738..740] to)
                (NP
                  (NP (NN:[741..746] point) (NNS:[747..756] mutations))
                  (PP (IN:[757..759] at)
                    (NP
                      (NP (CD:[760..763] one))
                      (PP (IN:[764..766] of)
                        (NP
                          (NP (CD:[767..770] two) (JJ:[772..777] major)
                              (``:[778..779] ") (JJ:[779..782] hot)
                              (NNS:[783..788] spots) ('':[788..789] "))
                          (PP (IN:[790..792] in)
                            (NP (DT:[793..796] the) (NN:[797..800] ras)
                                (NN:[801..807] coding) (NN:[808..816] sequence))))))))))))))
    (.:[816..817] .)))

;section 7 Span:821..865
;PMID: 6587382 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[821..825] PMID) (::[825..826] :) (CD:[827..834] 6587382)
        (NN:[835..836] -LSB-) (NNP:[836..842] PubMed) (::[843..844] -)
        (NN:[845..852] indexed) (IN:[853..856] for)
        (NNP:[857..865] MEDLINE-RSB-)))
